Futura Medical PLC, a consumer healthcare company specializing in the development and global commercialization of innovative sexual health products, is set to release its unaudited results for the six months ended 30 June 2024 on Tuesday 10 September 2024. The company will be hosting a webinar for retail investors via the Investor Meet Company platform at 9:00am BST on the same day. The presentation is open to all existing and potential shareholders, and questions can be submitted beforehand or during the live presentation.
Investors can register for the presentation via the provided link. Additionally, management will be hosting a webinar for analysts at 11:00am BST on the same day, and interested parties can register by contacting [email protected].
Futura Medical PLC is the developer of innovative sexual health products, with their lead product being Eroxon, a topically delivered gel formulation developed for the treatment of Erectile Dysfunction ("ED"). Eroxon is the only topical gel treatment for ED available over the counter and is designed to help men achieve an erection in ten minutes, addressing significant unmet needs in the ED market. The company's core strength lies in research, development, and commercialization of such products.
The prevalence of ED is highlighted, with 1 in 5 men globally across all adult age brackets being impacted, and approximately half of all men over 40 experiencing ED, with 25% of all new diagnoses occurring in men under 40. This underscores the significant market need that Futura Medical PLC aims to address with its innovative products.